Vertex Pharmaceuticals executive Charles F. Wagner Jr. reported a tax-related share disposition. On February 10, 2026, he transferred 3,045 shares of Vertex common stock at $468.41 per share under code F, which reflects payment of tax liability by delivering shares.
After this transaction, Wagner directly beneficially owned 48,280 shares of Vertex common stock. The filing characterizes the move as a tax-withholding disposition rather than an open-market purchase or sale.
Vertex Pharmaceuticals executive Ourania Tatsis reported two stock transactions. On February 11, 2026, she executed an open-market sale of 466 shares of common stock at $460.43 per share, leaving her with 51,436 directly owned shares.
On February 10, 2026, 2,140 shares were disposed of at $468.41 per share to cover tax obligations, a transaction coded as F. The sale was made under a company-approved Rule 10b5-1 trading plan that was entered into on August 21, 2025.
Vertex Pharmaceuticals executive Amit Sachdev reported a tax-related share disposition. On 02/10/2026, 2,057 shares of Vertex common stock were disposed of in a tax-withholding transaction at $468.41 per share. After this, he held 68,941 shares directly.
He also reported indirect ownership of 882 shares through a 401(k) plan and 9,301 shares held in a trust. The filing reflects equity compensation and related tax withholding rather than an open-market trade.
Vertex Pharmaceuticals executive reports tax-withholding share disposition. EVP and Chief Commercial Officer McKechnie Duncan transferred 1,127 shares of Vertex common stock on February 10, 2026 in a tax-withholding disposition priced at $468.41 per share, used to cover tax obligations related to equity compensation.
After this transaction, Duncan directly beneficially owned 21,811 shares of Vertex common stock. The transaction is coded "F," indicating payment of an exercise price or tax liability by delivering already-owned securities rather than an open-market sale.
Vertex Pharmaceuticals CEO & President Reshma Kewalramani reported an automatic share disposition related to taxes. On 02/10/2026, 8,297 shares of Vertex common stock were disposed of at $468.41 per share in a transaction coded "F", which indicates payment of a tax liability by delivering shares rather than a market trade. After this tax-withholding transaction, she directly beneficially owned 146,528 shares of Vertex common stock.
Vertex Pharmaceuticals executive Mark E. Bunnage, EVP and Chief Scientific Officer, reported two transactions in Vertex common stock. On February 11, 2026, he made an open-market sale of 2,021 shares at $460.43 per share. On February 10, 2026, 1,127 shares were disposed of at $468.41 per share to cover tax obligations. After these transactions, he directly owns 12,914 shares of Vertex common stock. The filing notes the sale was made under a company-approved Rule 10b5-1 trading plan entered into on November 26, 2025, indicating the trades were pre-scheduled rather than discretionary.
Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported a tax-related share disposition. On 02/10/2026, 2,145 shares of Vertex common stock were disposed of at $468.41 per share in a transaction coded "F," which indicates shares were used to satisfy a tax liability. After this transaction, Bozic directly owned 41,857 shares of Vertex common stock.
Vertex Pharmaceuticals executive Jonathan Biller reported share sales and tax-related share dispositions. On 02/11/2026, he sold 1,925 shares of Vertex common stock in an open-market transaction at $460.43 per share under a company-approved Rule 10b5-1 trading plan.
On 02/10/2026, 1,630 shares were disposed of at $468.41 per share to satisfy tax obligations by delivering shares. Following these transactions, Biller directly owned 20,819 shares of Vertex common stock.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III, EVP and Chief Technical Operations Officer, reported two stock transactions in February 2026. On February 10, 2026, he disposed of 872 shares of common stock to cover tax obligations at a price of $468.41 per share. On February 11, 2026, he executed an open-market sale of 1,751 shares of common stock at $460.43 per share, made under a company-approved Rule 10b5-1 trading plan entered into on August 11, 2025. After these transactions, he directly owned 22,046 shares of Vertex common stock.
Vertex Pharmaceuticals executive Kristen Ambrose reported insider share sales and tax-related share withholding. On February 11, 2026, she completed an open-market sale of 1,376 shares of common stock at $460.43 per share. On February 10, 2026, 592 shares were disposed of at $468.41 per share to cover tax or exercise-related obligations.
Following these transactions, Ambrose directly owned 10,127 shares of Vertex common stock. The sales were made under a company-approved Rule 10b5-1 trading plan that was entered into on August 8, 2025, indicating the trades were pre-arranged rather than discretionary decisions at the time of sale.